A publication from Acta Pharmaceutica Sinica B discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a debilitating ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and ...
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial. The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 for the acute treatment of ...
G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and ...
This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results